Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
出版年份 2019 全文链接
标题
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
作者
关键词
-
出版物
DRUG SAFETY
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-04-11
DOI
10.1007/s40264-019-00812-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio
- (2018) Masayuki Kaneko et al. ANNALS OF PHARMACOTHERAPY
- Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist
- (2018) Eva W. Iepsen et al. Cell Metabolism
- Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity
- (2018) Christina C. Nexøe-Larsen et al. DIABETES OBESITY & METABOLISM
- Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss
- (2018) Jens Juul Holst et al. Surgery for Obesity and Related Diseases
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- (2018) Erin A. Bohula et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cracking the combination: Gut hormones for the treatment of obesity and diabetes
- (2018) Kleopatra Alexiadou et al. JOURNAL OF NEUROENDOCRINOLOGY
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
- (2017) Giovanna Muscogiuri et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
- (2016) Igho J. Onakpoya et al. BMC Medicine
- Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning
- (2016) Marina V. Basalay et al. CARDIOVASCULAR RESEARCH
- Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients
- (2016) Mark M. Smits et al. DIABETES OBESITY & METABOLISM
- Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes
- (2016) P. Mensberg et al. DIABETES OBESITY & METABOLISM
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Weight management in obesity - past and present
- (2016) D. Haslam INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
- (2016) Claire L Meek et al. PEPTIDES
- Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus
- (2016) Lotte Bjerre Knudsen et al. Journal of Diabetes Investigation
- Probability of an Obese Person Attaining Normal Body Weight: Cohort Study Using Electronic Health Records
- (2015) Alison Fildes et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes
- (2015) Cristina Hernández et al. DIABETES
- A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
- (2015) Michael A. Nauck et al. DIABETES CARE
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
- (2014) E W Iepsen et al. INTERNATIONAL JOURNAL OF OBESITY
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
- (2014) Gian Paolo Fadini et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications
- (2013) S. Madsbad DIABETES OBESITY & METABOLISM
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
- (2013) Sharon A. Sadry et al. Nature Reviews Endocrinology
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
- (2013) Obesity
- Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery
- (2013) M. Fried et al. OBESITY SURGERY
- Alterations in energy balance following exenatide administration
- (2012) David P. Bradley et al. Applied Physiology Nutrition and Metabolism
- Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders
- (2012) Isidro Salcedo et al. BRITISH JOURNAL OF PHARMACOLOGY
- Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight
- (2012) J. Jelsing et al. DIABETES OBESITY & METABOLISM
- GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation
- (2012) Lars Wichmann Madsen et al. ENDOCRINOLOGY
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
- (2011) R. R. Wing et al. DIABETES CARE
- Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
- (2011) Scott E. Kanoski et al. ENDOCRINOLOGY
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
- (2011) S. S. Torekov et al. Obesity Reviews
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group
- (2010) Jeff J. Guo et al. VALUE IN HEALTH
- The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis
- (2009) Daphne P Guh et al. BMC PUBLIC HEALTH
- Annual Medical Spending Attributable To Obesity: Payer-And Service-Specific Estimates
- (2009) Eric A. Finkelstein et al. HEALTH AFFAIRS
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- The Medical Risks of Obesity
- (2009) Xavier Pi-Sunyer POSTGRADUATE MEDICINE
- Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
- (2008) Diana L. Williams et al. ENDOCRINOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now